Pliant Therapeutics Shares it 52-Week Low
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Fintel on MSN21d
JP Morgan Downgrades Pliant Therapeutics (PLRX)Fintel reports that on February 10, 2025, JP Morgan downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Overweight to Neutral. Analyst Price Forecast Suggests 1,212.38% Upside As of ...
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.
Pliant Therapeutics (NASDAQ:PLRX) experienced a significant adjustment in their stock price target as Needham analysts revised their expectations from $38.00 to $10.00. Despite the reduction, Needham ...
https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-raised-to-30-from-24-at-td-cowen JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral ...
The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback